Actinogen Advances Alzheimer's Trial with Positive Regulatory Feedback and Strong Cash Position

XanaMIA Trial Progresses Toward Pivotal Readout

Actinogen Medical’s (ASX:ACW) pivotal XanaMIA phase 2b/3 Alzheimer’s disease trial remains firmly on course to deliver topline results in November 2026. The trial, fully enrolled with 247 participants, has passed a third independent Data Monitoring Committee (DMC) safety review, which recommended continuation without changes. This endorsement adds to prior positive DMC recommendations and reinforces confidence in the trial’s ongoing conduct.

Meanwhile, the open-label extension (OLE) phase, launched in March 2026, is gaining strong traction with 81 patients now receiving active Xanamem therapy. Notably, 88% of participants completing the randomized phase have rolled over into the OLE, which offers up to 25 months of active treatment and collects extended safety and observational efficacy data, including on the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB).

Regulatory Pathway Clarified by EMA and FDA Alignment

Actinogen’s regulatory strategy received a significant boost from positive scientific advice from the European Medicines Agency (EMA) in May, which closely aligns with prior guidance from the US Food and Drug Administration (FDA). Both agencies have agreed on key aspects such as the suitability of regulatory starting materials for commercial manufacturing and the design parameters for a second pivotal phase 3 trial following a positive XanaMIA outcome.

The EMA and FDA feedback also clarified safety database requirements and ancillary studies, providing a clearer roadmap toward marketing approval in major jurisdictions. While the company still plans a second pivotal trial, it is exploring options to seek approvals based on a single trial pending November’s results. This regulatory clarity supports ongoing commercial discussions and validates Xanamem’s late-stage development pathway.

Antidepressant Activity Published in Leading Psychiatry Journal

Adding to the clinical momentum, Actinogen published results from its phase 2 depression trial in the British Journal of Psychiatry. The study demonstrated clinically and sometimes statistically significant antidepressant effects of Xanamem in patients with major depressive disorder and cognitive impairment, a notoriously difficult-to-treat population. The strongest benefits appeared during the blinded follow-up period, particularly among patients on standard antidepressants.

The trial did not show cognitive improvement benefits, possibly due to a high placebo response, but Xanamem’s safety profile remained consistent with previous studies. This publication not only validates the drug’s mechanism of action but also opens potential new therapeutic avenues beyond Alzheimer’s disease.

Intellectual Property and Commercial Readiness

Actinogen continues to fortify its intellectual property portfolio, securing national patent acceptances in Australia, Russia, China, and Chile. These patents cover Xanamem’s use for cognitive decline in healthy elderly individuals, manufacturing processes, and patient selection methods. Additionally, China’s new six-year data exclusivity rule may offer further protection against generic competition.

Commercially, the company is actively engaging with Alzheimer’s disease key opinion leaders and potential partners worldwide, intensifying efforts as the pivotal trial results approach. This groundwork aims to ensure rapid evaluation and positioning of Xanamem in the market.

Financial Position Supports Milestones Through Mid-2027

Actinogen closed the June quarter with $16.7 million in cash, providing a runway well beyond the anticipated November topline results. Operating expenditure for the quarter was $5.0 million, primarily funding the XanaMIA trial and its open-label extension. The company also benefits from a non-dilutive $4.32 million funding facility secured against its FY26 R&D tax incentive, with repayments due by year-end.

CEO Dr Steven Gourlay highlighted the quarter’s achievements, emphasising the antidepressant data as a strong validation of Xanamem’s brain activity and noting the continued regulatory and commercial progress. The company remains focused on delivering the pivotal trial results that could transform Alzheimer’s treatment options.